Skip to search formSkip to main contentSkip to account menu

AN2728

Known as: AN-2728 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Boron CompoundsBridged Bicyclo Compounds, Heterocyclic

Narrower (1)

crisaborole

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Half- and Mixed-Sandwich Transition Metal Dicarbollides andnido-Carboranes(-1) for Medicinal Applications
Today, medicinal chemistry is still clearly dominated by organic chemistry, and most of the marketed drugs are purely organic… 
2015
2015
Maximal use systemic exposure study evaluating AN2728, a novel boron-based small molecule, for the treatment of pediatric and adolescent subjects with mild-to-moderate atopic dermatitis (THER2P.959)
AN2728, a novel boron-based compound, inhibits phosphodiesterase-4 and reduces proinflammatory cytokine production possibly… 
2015
2015
AN2728, a new boron-based topical anti-inflammatory agent, inhibits phosphodiesterase 4 (IRC4P.611)
The novel boron-containing compound, AN2728, is being investigated in phase 3 trials for atopic dermatitis treatment. It exerts… 
2014
2014
AN-2728: Phosphodiesterase PDE4 inhibitor, treatment of atopic dermatitis, treatment of psoriasis
2014
2014
Biogen Idec enters hemophilia B market
mildly effective, but tried and true, first-line drugs like metformin and the sulfonylureas, and innovative injectables such as… 
2010
2010
Gateways to clinical trials.
(-)-Epigallocatechin gallate, Abafungin, ACE-031, Adapalene/benzoyl peroxide, AE-37, Aflibercept, AGS-003, Albiglutide… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)